Thermo Fisher Scientific Inc. (0R0H.L)
USD 444.49
(-5.68%)
USD 444.49
(-5.68%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 31.3 Billion USD | 8.73% |
| 2022 | 28.79 Billion USD | -10.43% |
| 2021 | 32.14 Billion USD | 67.91% |
| 2020 | 19.14 Billion USD | 12.04% |
| 2019 | 17.08 Billion USD | -4.25% |
| 2018 | 17.84 Billion USD | -6.05% |
| 2017 | 18.99 Billion USD | 22.7% |
| 2016 | 15.48 Billion USD | 35.37% |
| 2015 | 11.43 Billion USD | -7.41% |
| 2014 | 12.35 Billion USD | 29.95% |
| 2013 | 9.5 Billion USD | 35.18% |
| 2012 | 7.03 Billion USD | 22.17% |
| 2011 | 5.75 Billion USD | 183.33% |
| 2010 | 2.03 Billion USD | -1.67% |
| 2009 | 2.06 Billion USD | 1.1% |
| 2008 | 2.04 Billion USD | -0.12% |
| 2007 | 2.04 Billion USD | -6.18% |
| 2006 | 2.18 Billion USD | 365.34% |
| 2005 | 468.63 Million USD | 107.29% |
| 2004 | 226.07 Million USD | -1.5% |
| 2003 | 229.5 Million USD | -49.15% |
| 2002 | 451.34 Million USD | -38.0% |
| 2001 | 728 Million USD | -52.36% |
| 2000 | 1.52 Billion USD | -2.43% |
| 1999 | 1.56 Billion USD | -22.7% |
| 1998 | 2.02 Billion USD | 16.24% |
| 1997 | 1.74 Billion USD | 12.45% |
| 1996 | 1.55 Billion USD | 38.89% |
| 1995 | 1.11 Billion USD | 6.31% |
| 1994 | 1.04 Billion USD | 62.13% |
| 1993 | 647.5 Million USD | 31.02% |
| 1992 | 494.2 Million USD | 93.8% |
| 1991 | 255 Million USD | 21.43% |
| 1990 | 210 Million USD | 22.02% |
| 1989 | 172.1 Million USD | 15.89% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 31.19 Billion USD | 3.01% |
| 2024 Q1 | 31.15 Billion USD | -0.48% |
| 2024 Q2 | 30.28 Billion USD | -2.8% |
| 2023 Q1 | 29 Billion USD | 0.74% |
| 2023 Q3 | 30.44 Billion USD | 4.94% |
| 2023 FY | 31.3 Billion USD | 8.73% |
| 2023 Q2 | 29 Billion USD | -0.0% |
| 2023 Q4 | 31.3 Billion USD | 2.85% |
| 2022 Q1 | 31.2 Billion USD | -2.92% |
| 2022 FY | 28.79 Billion USD | -10.43% |
| 2022 Q4 | 28.79 Billion USD | 3.09% |
| 2022 Q3 | 27.93 Billion USD | -3.85% |
| 2022 Q2 | 29.05 Billion USD | -6.91% |
| 2021 Q3 | 21.58 Billion USD | 14.88% |
| 2021 Q4 | 32.14 Billion USD | 48.95% |
| 2021 Q1 | 18.65 Billion USD | -2.59% |
| 2021 FY | 32.14 Billion USD | 67.91% |
| 2021 Q2 | 18.78 Billion USD | 0.73% |
| 2020 Q2 | 20.67 Billion USD | 7.32% |
| 2020 Q3 | 21.1 Billion USD | 2.1% |
| 2020 Q4 | 19.14 Billion USD | -9.28% |
| 2020 FY | 19.14 Billion USD | 12.04% |
| 2020 Q1 | 19.26 Billion USD | 12.71% |
| 2019 Q4 | 17.08 Billion USD | 4.06% |
| 2019 FY | 17.08 Billion USD | -4.25% |
| 2019 Q1 | 16.91 Billion USD | -5.24% |
| 2019 Q3 | 16.42 Billion USD | -1.71% |
| 2019 Q2 | 16.7 Billion USD | -1.2% |
| 2018 Q3 | 17.94 Billion USD | 0.33% |
| 2018 Q4 | 17.84 Billion USD | -0.51% |
| 2018 FY | 17.84 Billion USD | -6.05% |
| 2018 Q1 | 18.28 Billion USD | -3.75% |
| 2018 Q2 | 17.88 Billion USD | -2.2% |
| 2017 Q1 | 15.3 Billion USD | -1.15% |
| 2017 FY | 18.99 Billion USD | 22.7% |
| 2017 Q3 | 19.32 Billion USD | 25.87% |
| 2017 Q4 | 18.99 Billion USD | -1.71% |
| 2017 Q2 | 15.35 Billion USD | 0.34% |
| 2016 Q1 | 11.66 Billion USD | 1.97% |
| 2016 Q2 | 11.63 Billion USD | -0.26% |
| 2016 Q3 | 16.94 Billion USD | 45.64% |
| 2016 Q4 | 15.48 Billion USD | -8.61% |
| 2016 FY | 15.48 Billion USD | 35.37% |
| 2015 Q3 | 10.27 Billion USD | -3.98% |
| 2015 FY | 11.43 Billion USD | -7.41% |
| 2015 Q1 | 10.7 Billion USD | -13.29% |
| 2015 Q2 | 10.7 Billion USD | -0.05% |
| 2015 Q4 | 11.43 Billion USD | 11.27% |
| 2014 Q4 | 12.35 Billion USD | 8.4% |
| 2014 Q3 | 11.39 Billion USD | -8.87% |
| 2014 Q2 | 12.5 Billion USD | -17.76% |
| 2014 Q1 | 15.2 Billion USD | 59.95% |
| 2014 FY | 12.35 Billion USD | 29.95% |
| 2013 Q1 | 6.72 Billion USD | -4.36% |
| 2013 Q4 | 9.5 Billion USD | 41.48% |
| 2013 Q3 | 6.71 Billion USD | -0.05% |
| 2013 Q2 | 6.72 Billion USD | -0.05% |
| 2013 FY | 9.5 Billion USD | 35.18% |
| 2012 FY | 7.03 Billion USD | 22.17% |
| 2012 Q4 | 7.03 Billion USD | -0.09% |
| 2012 Q3 | 7.03 Billion USD | 22.48% |
| 2012 Q1 | 5.75 Billion USD | -0.07% |
| 2012 Q2 | 5.74 Billion USD | -0.09% |
| 2011 FY | 5.75 Billion USD | 183.33% |
| 2011 Q4 | 5.75 Billion USD | -5.89% |
| 2011 Q3 | 6.11 Billion USD | 52.55% |
| 2011 Q2 | 4 Billion USD | 122.61% |
| 2011 Q1 | 1.8 Billion USD | -11.35% |
| 2010 Q1 | 1.93 Billion USD | -6.56% |
| 2010 FY | 2.03 Billion USD | -1.67% |
| 2010 Q3 | 3.3 Million USD | -99.84% |
| 2010 Q4 | 2.03 Billion USD | 61454.55% |
| 2010 Q2 | 2.03 Billion USD | 5.31% |
| 2009 FY | 2.06 Billion USD | 1.1% |
| 2009 Q2 | 2.02 Billion USD | 0.18% |
| 2009 Q1 | 2.02 Billion USD | -0.93% |
| 2009 Q4 | 2.06 Billion USD | 5.16% |
| 2009 Q3 | 1.96 Billion USD | -3.14% |
| 2008 Q2 | 2.04 Billion USD | -0.07% |
| 2008 Q1 | 2.04 Billion USD | 0.0% |
| 2008 FY | 2.04 Billion USD | -0.12% |
| 2008 Q3 | 2.04 Billion USD | -0.07% |
| 2008 Q4 | 2.04 Billion USD | 0.02% |
| 2007 Q2 | 2.17 Billion USD | -0.22% |
| 2007 Q1 | 2.18 Billion USD | 0.08% |
| 2007 FY | 2.04 Billion USD | -6.18% |
| 2007 Q3 | 2.18 Billion USD | 0.16% |
| 2007 Q4 | 2.04 Billion USD | -6.2% |
| 2006 FY | 2.18 Billion USD | 365.34% |
| 2006 Q3 | 469.88 Million USD | 0.52% |
| 2006 Q1 | 469.21 Million USD | 0.12% |
| 2006 Q2 | 467.46 Million USD | -0.37% |
| 2006 Q4 | 2.18 Billion USD | 364.09% |
| 2005 Q4 | 468.63 Million USD | -0.73% |
| 2005 Q1 | 210.91 Million USD | -6.7% |
| 2005 FY | 468.63 Million USD | 107.29% |
| 2005 Q2 | 472.93 Million USD | 124.23% |
| 2005 Q3 | 472.09 Million USD | -0.18% |
| 2004 Q2 | 224.54 Million USD | -3.55% |
| 2004 Q1 | 232.79 Million USD | 1.43% |
| 2004 Q3 | 228.43 Million USD | 1.73% |
| 2004 FY | 226.07 Million USD | -1.5% |
| 2004 Q4 | 226.07 Million USD | -1.04% |
| 2003 FY | 229.5 Million USD | -49.15% |
| 2003 Q1 | 435.86 Million USD | -3.43% |
| 2003 Q2 | 226.59 Million USD | -48.01% |
| 2003 Q3 | 218.84 Million USD | -3.42% |
| 2003 Q4 | 229.5 Million USD | 4.87% |
| 2002 Q1 | 717 Million USD | -1.51% |
| 2002 Q2 | 656 Million USD | -8.51% |
| 2002 Q4 | 451.34 Million USD | -14.68% |
| 2002 Q3 | 529 Million USD | -19.36% |
| 2002 FY | 451.34 Million USD | -38.0% |
| 2001 FY | 728 Million USD | -52.36% |
| 2001 Q4 | 728 Million USD | -46.35% |
| 2001 Q3 | 1.35 Billion USD | -8.31% |
| 2001 Q2 | 1.48 Billion USD | -1.17% |
| 2001 Q1 | 1.49 Billion USD | -2.0% |
| 2000 Q4 | 1.52 Billion USD | -1.69% |
| 2000 Q1 | 1.57 Billion USD | 0.26% |
| 2000 Q2 | 1.57 Billion USD | 0.13% |
| 2000 Q3 | 1.55 Billion USD | -1.13% |
| 2000 FY | 1.52 Billion USD | -2.43% |
| 1999 Q2 | 1.98 Billion USD | -1.88% |
| 1999 Q4 | 1.56 Billion USD | -17.92% |
| 1999 Q3 | 1.9 Billion USD | -3.83% |
| 1999 Q1 | 2.02 Billion USD | 11.77% |
| 1999 FY | 1.56 Billion USD | -22.7% |
| 1998 Q2 | 1.95 Billion USD | -1.52% |
| 1998 Q3 | 1.89 Billion USD | -2.82% |
| 1998 Q1 | 1.98 Billion USD | 13.6% |
| 1998 FY | 2.02 Billion USD | 16.24% |
| 1998 Q4 | 1.8 Billion USD | -4.54% |
| 1997 Q2 | 1.47 Billion USD | -1.53% |
| 1997 Q3 | 1.77 Billion USD | 19.68% |
| 1997 Q4 | 1.74 Billion USD | -1.53% |
| 1997 FY | 1.74 Billion USD | 12.45% |
| 1997 Q1 | 1.5 Billion USD | -3.1% |
| 1996 Q3 | 1.4 Billion USD | -15.03% |
| 1996 Q4 | 1.55 Billion USD | 10.09% |
| 1996 FY | 1.55 Billion USD | 38.89% |
| 1996 Q1 | 1.61 Billion USD | 44.54% |
| 1996 Q2 | 1.65 Billion USD | 2.54% |
| 1995 Q3 | 1.07 Billion USD | 0.54% |
| 1995 Q1 | 1.03 Billion USD | -1.79% |
| 1995 Q2 | 1.07 Billion USD | 3.98% |
| 1995 Q4 | 1.11 Billion USD | 3.73% |
| 1995 FY | 1.11 Billion USD | 6.31% |
| 1994 FY | 1.04 Billion USD | 62.13% |
| 1994 Q3 | 1.06 Billion USD | -5.83% |
| 1994 Q4 | 1.04 Billion USD | -1.61% |
| 1994 Q2 | 1.13 Billion USD | 41.45% |
| 1994 Q1 | 801 Million USD | 23.71% |
| 1993 Q2 | 473.1 Million USD | -2.29% |
| 1993 Q1 | 484.2 Million USD | -2.02% |
| 1993 Q4 | 647.5 Million USD | 22.82% |
| 1993 FY | 647.5 Million USD | 31.02% |
| 1993 Q3 | 527.2 Million USD | 11.44% |
| 1992 Q1 | 247.8 Million USD | -2.82% |
| 1992 Q2 | 236.5 Million USD | -4.56% |
| 1992 Q4 | 494.2 Million USD | 4.2% |
| 1992 FY | 494.2 Million USD | 93.8% |
| 1992 Q3 | 474.3 Million USD | 100.55% |
| 1991 Q1 | 278.4 Million USD | 32.57% |
| 1991 Q3 | 263.7 Million USD | -0.3% |
| 1991 Q4 | 255 Million USD | -3.3% |
| 1991 FY | 255 Million USD | 21.43% |
| 1991 Q2 | 264.5 Million USD | -4.99% |
| 1990 Q3 | 216.3 Million USD | 18.46% |
| 1990 FY | 210 Million USD | 22.02% |
| 1990 Q1 | 163.9 Million USD | -4.76% |
| 1990 Q2 | 182.6 Million USD | 11.41% |
| 1990 Q4 | 210 Million USD | -2.91% |
| 1989 FY | 172.1 Million USD | 15.89% |
| 1989 Q3 | 187 Million USD | 0.0% |
| 1989 Q4 | 172.1 Million USD | -7.97% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -23971.041% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -54837.882% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -7972.026% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -68418.154% |
| bluebird bio, Inc. | 224.41 Million USD | -13850.69% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -84335.934% |
| Imunon, Inc. | 1.13 Million USD | -2747920.044% |
| Editas Medicine, Inc. | 24.37 Million USD | -128358.887% |
| IQVIA Holdings Inc. | 12.95 Billion USD | -141.667% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | -1484.774% |
| Myriad Genetics, Inc. | 130.9 Million USD | -23817.494% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -12020.79% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -94212.568% |
| Verastem, Inc. | 40.08 Million USD | -78002.081% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | -289.209% |
| Waters Corporation | 2.3 Billion USD | -1257.962% |
| Biogen Inc. | 7.18 Billion USD | -335.547% |
| Nektar Therapeutics | 112.62 Million USD | -27698.446% |
| Perrigo Company plc | 3.63 Billion USD | -761.815% |
| Dynavax Technologies Corporation | 252.41 Million USD | -12303.236% |
| Illumina, Inc. | 1.48 Billion USD | -2002.619% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -966604.759% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -3130700.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -17918.682% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -132904.801% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -5178.75% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -93314.889% |
| Evolus, Inc. | 120.35 Million USD | -25912.18% |
| Adicet Bio, Inc. | 17.7 Million USD | -176751.381% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1018377.554% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -1058.311% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -6142.299% |
| FibroGen, Inc. | 89.69 Million USD | -34804.177% |
| Agilent Technologies, Inc. | 2.73 Billion USD | -1044.717% |
| OPKO Health, Inc. | 222.03 Million USD | -14000.543% |
| Homology Medicines, Inc. | 43.17 Million USD | -72412.507% |
| Geron Corporation | 35.05 Million USD | -89221.275% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | -1236.222% |
| Exelixis, Inc. | 189.94 Million USD | -16382.753% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -3344771.795% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -32260.693% |
| Zoetis Inc. | 6.56 Billion USD | -376.965% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -17481.85% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -711122.172% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -4220.132% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -91470.635% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -2135.685% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -2664.467% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -1988.247% |
| Blueprint Medicines Corporation | 610.96 Million USD | -5024.378% |
| Insmed Incorporated | 1.19 Billion USD | -2523.534% |
| TG Therapeutics, Inc. | 100.11 Million USD | -31171.1% |
| Incyte Corporation | 29.16 Million USD | -107258.892% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -6911.87% |